ARWR · Arrowhead Pharmaceuticals, Inc.
AI read · Good for ARWR
The AI's read
These results make Arrowhead's brain-delivery approach more credible and support continued work on ARO-MAPT. The reported tau reductions lasted through day 105, and participants mostly had mild side effects. The main limit is that the results came from healthy volunteers. Whether the drug helps people with Alzheimer's think better or slows the disease is still being studied in patients.